AceIRx Presentations For The October 12, 2018 Meeting Of The FDA Anesthetic & Analgesic Drug Products Advisory Committee

The presentation was given on October 12, 2018, by AcelRx to a meeting of the FDA Anesthetic & Analgesic Drug Products Advisory Committee. The presentation discusses DSUVIA, a single-dose 30 mcg sublingual tablet of sufentanil, a new very potent synthetic opioid. DSUVIA is intended for non-invasive management of moderate-to-severe pain in medically supervised settings. The panel recommended that the FDA approve the medication; however, the FDA is not required to accept the recommendation . . .